SYK and acute myeloid leukemia: Furthermore, first clinical data of the oral spleen tyrosine kinase (SYK) inhibitor entospletinib given in combination with intensive chemotherapy in NPM1-mutated AML showed promising activity42 and triggered a double-blinded randomized phase-III evaluation (ClinicalTrials.gov Identifier: NCT05020665).